- Previous Close
125.92 - Open
126.03 - Bid 125.54 x 1000
- Ask 125.87 x 800
- Day's Range
125.72 - 127.85 - 52 Week Range
99.14 - 134.63 - Volume
6,033,370 - Avg. Volume
8,269,249 - Market Cap (intraday)
318.932B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
141.40 - EPS (TTM)
0.89 - Earnings Date Jul 30, 2024
- Forward Dividend & Yield 3.08 (2.45%)
- Ex-Dividend Date Sep 16, 2024
- 1y Target Est
143.28
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
www.merck.com70,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MRK
View MorePerformance Overview: MRK
Trailing total returns as of 7/25/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRK
View MoreValuation Measures
Market Cap
318.93B
Enterprise Value
347.53B
Trailing P/E
139.91
Forward P/E
14.62
PEG Ratio (5yr expected)
0.10
Price/Sales (ttm)
5.22
Price/Book (mrq)
7.90
Enterprise Value/Revenue
5.66
Enterprise Value/EBITDA
38.70
Financial Highlights
Profitability and Income Statement
Profit Margin
3.76%
Return on Assets (ttm)
10.26%
Return on Equity (ttm)
5.31%
Revenue (ttm)
61.4B
Net Income Avi to Common (ttm)
2.31B
Diluted EPS (ttm)
0.89
Balance Sheet and Cash Flow
Total Cash (mrq)
5.62B
Total Debt/Equity (mrq)
84.65%
Levered Free Cash Flow (ttm)
9.59B
Research Analysis: MRK
View MoreCompany Insights: MRK
MRK does not have Company Insights
Research Reports: MRK
View MoreThe Argus Min Vol Model Portfolio
Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.
The Argus Min Vol Model Portfolio
Rapidly rising inflation in 2022 knocked stocks into a bear market. While growth strategies suffered the most, value strategies also declined. Even bond prices were lower that year. Stocks have recovered and a new bull market has started, but gains have been largely driven by only a handful of high-tech companies. Inflation remains an issue and the Federal Reserve has yet to lower rates. Is a recession in the offing? With all the uncertainty, what's a potential equity strategy for investors amid all the uncertainty? Argus believes that Min Vol is an all-weather strategy that is timely in any investing climate. Academic literature and, more to the point, returns history, indicate that Min Vol can deliver market-matching returns on an absolute basis and superior returns on a risk-adjusted basis over various time periods.
Argus Quick Note: Weekly Stock List for 06/17/2024: Focus List Changes
Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.
Argus Adjusts Sector Ratings
We have reviewed our recommended sector allocations this month, and based on the analysis we have adjusted our current sector Over-Weight, Under-Weight, and Market-Weight recommendations. Our multi-factor model includes a performance-ranking system, which assigns points for monthly, quarterly, and YTD sector performance versus the benchmark S&P 500; current sector P/E versus five-year P/E, with points awarded for discount to S&P 500 current versus five-year P/E delta; two-year earnings growth, with points awarded for exceeding the benchmark average and for EPS acceleration; relative performance to the sector group average; sector conviction, meaning BUY rating percentage per sector versus total Argus BUY-rating percentage; and PEG ratio, with points awarded or subtracted based on sector PEG ratios below or above the group average. Our process yielded 42 total points, for an average sector score of 3.8. To earn an Over-Weight designation, sectors had to score five points or above; for Market-Weight, three or four points; and for Under-Weight, two points or below. Our current Over-Weight sectors are Healthcare, Communication Services, Financial, and Information Technology. Our current Market-Weight sectors are Consumer Discretionary, Energy (raised from Under-Weight), Industrials, Real Estate and Utilities. Our Under-Weight sectors are Materials and Consumer Staples. We suggest that advisors and investors leverage this consistent and comprehensive process to adjust sector weightings within their diversified equity portfolios, with a primary focus on the largest sectors.